Bladder cancer · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | — | R 286 955 | 14d | ~4.7 mo | ~11.5 mo | ~2 | ~R 573 911 PFS proxy · indirect | 4 |
Intravesicular Mitomycin monotherapy Variant #01 | — | R 11 410 | 90d | — | — | ~6 | ~R 45 641 indirect | — |
Intravesicular Gemcitabine monotherapy Variant #01 | — | R 1 672 | — | — | — | ~1 | ~R 1 672 indirect | — |
Intravesicular Doxorubicin monotherapy Variant #01 | — | R 564 | 30d | — | — | ~11 | ~R 4 508 indirect | — |
BCG vaccine and Nogapendekin alfa inbakicept Variant #01 Partial | — | — | 7d | — | — | ~6 | — | — |
BCG vaccine monotherapy Variant #01 Partial | — | — | 30d | — | ~38.6 mo | ~1 | — | 1 |
Intravesicular Thiotepa monotherapy Variant #01 Partial | — | — | 30d | — | — | ~11 | — | — |
Intravesicular Valrubicin monotherapy Variant #01 Partial | — | — | 42d | — | — | ~1 | — | — |
Nadofaragene firadenovec monotherapy Variant #01 Partial | — | — | 90d | — | — | ~4 | — | — |
9 of 9 regimens shown